Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

Direct Sales At Lower Prices?

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

big opportunity
Trump’s Executive Orders May Positively Impact Biosimilar Industry (Shutterstock)

More from South Korea

More from Drug Pricing